Synthesis, Characterization and Study the Biological Activity for New Schiff base Compound 2-(((1E,2E)-1,2-diphenyl-2-((4-(E-1-(thiazol-2-ylimino) ethyl) phenyl) imino) ethylidene) amino) phenol (DEAP)

Document Type : Research Paper


1 Department of Chemistry, College of Education, University of Al-Qadisiyah, Iraq

2 Department of Chemistry, College of Education, University of Al-Qadisiyah, Diwaniyah, Iraq


The synthesis of the Schiff base compound (DEAP) 2-(((1E,2E)-1,2-diphenyl-2-((4-(E-1-(thiazol-2-ylimino) ethyl) phenyl)imino)ethylidene)amino)phenol (C31H24N4OS) was successfully executed via a two-step condensation reaction. The preliminary step involved generating compound (A) (E)-4-(1-(thiazo-2-ylimino)ethyl)aniline, using 2-aminothiazol and 4-aminoacetophenone. The secondary step involved the synthesis of compound (DEAP) from compound (A), benzil, and 2-aminophenol. Various spectral techniques, such as Elemental analysis (C.H.N), 1H,13C-NMR, Mass spectrum, UV-Vis, FT-IR, XRD, and FE-SEM were employed for structural analysis of DEAP. Furthermore, the biological activities of the compound were scrutinized, with microbial susceptibility tests conducted on five isolates: Staphylococcus aureus, streptococcus mutans, pseudomonas aeruginosa, E. coli, and candida albicans, using the microtiter plate to determine the MIC. Anticancer potential of DEAP was investigated via cell cytotoxicity trials and in vitro antitumor screening against prostate cancer line PC3 and breast cancer (MCF-7) cell lines, utilizing the colorimetric (MTT) assay for evaluating cellular viability. The findings indicate selective cytotoxicity of DEAP, detrimental to cancerous cell lines while sparing normal cells, marking it as a prospective candidate for future cytotoxic therapies. Hence, further investigation into DEAP's potential as an anticancer drug is warranted.